InfuSystem (NYSE:INFU) Rating Increased to Strong-Buy at B. Riley

InfuSystem (NYSE:INFU) was upgraded by stock analysts at B. Riley to a “strong-buy” rating in a research report issued on Wednesday, Zacks.com reports.

Separately, StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 20th.

InfuSystem Stock Up 10.2 %

Shares of INFU stock opened at $6.57 on Wednesday. InfuSystem has a 1-year low of $5.74 and a 1-year high of $10.99. The stock has a market cap of $140.07 million, a price-to-earnings ratio of -657,000.00 and a beta of 1.46. The company has a quick ratio of 1.64, a current ratio of 2.07 and a debt-to-equity ratio of 0.64.

InfuSystem (NYSE:INFU) last posted its earnings results on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). InfuSystem had a net margin of 0.28% and a return on equity of 0.70%. The company had revenue of $33.70 million during the quarter.

Hedge Funds Weigh In On InfuSystem

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INFU. Rhumbline Advisers increased its position in shares of InfuSystem by 13.8% during the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock worth $121,000 after acquiring an additional 2,145 shares during the period. Marshall Wace LLP acquired a new position in InfuSystem during the 2nd quarter worth $131,000. Oppenheimer Asset Management Inc. increased its holdings in InfuSystem by 52.1% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company’s stock worth $178,000 after purchasing an additional 8,917 shares during the period. Panagora Asset Management Inc. acquired a new stake in InfuSystem in the 2nd quarter valued at about $208,000. Finally, ARS Investment Partners LLC boosted its stake in shares of InfuSystem by 11.4% in the 2nd quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock valued at $229,000 after buying an additional 3,422 shares during the period. Hedge funds and other institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.